Current Colorectal Cancer Reports

, Volume 6, Issue 4, pp 212–220

Circulating Tumor Cells and Colorectal Cancer

Article

DOI: 10.1007/s11888-010-0069-7

Cite this article as:
Allen, J.E. & El-Deiry, W.S. Curr Colorectal Cancer Rep (2010) 6: 212. doi:10.1007/s11888-010-0069-7

Abstract

The significance of circulating tumor cells (CTCs) has been discussed for more than a century. The advent of modern technology has allowed for more reliable detection of CTCs, and recent studies have provided compelling evidence that CTCs predict clinical response in metastatic colorectal cancer (mCRC). Combination of CTC analysis with independent prognostic factors has demonstrated powerful synergy in some studies. The ability of CTCs to predict metastasis and therapy-specific response has high potential clinical utility, with early studies showing promising results in colorectal cancer (CRC). Reliable CTC detection has also allowed for examination of tumor cell dissemination during surgery, and there appears to be a heavy dependence on the approach chosen. This review discusses the evidence for CTC significance, with particular focus on detection methods, novel markers, and clinical outcomes in CRC. Numerous opportunities exist for preclinical, clinical, and translational studies to explore molecular determinants within CTCs, as well as the value of CTCs in directing targeted therapeutics.

Keywords

Circulating tumor cells Colorectal cancer CRC Colon cancer Rectal cancer CTC detection CTC enrichment Stratification Prognosis Overall survival Progression-free survival Clinical response Hepatic resection Liver resection Hepatic ablation Hepatic metastasis Liver metastasis Cytokeratin Tumor cell dissemination Epithelial cell adhesion molecule EpCAM Survivin Cetuximab KRAS 

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Penn State Hershey Cancer InstituteHersheyUSA
  2. 2.Hematology/Oncology DivisionPenn State Hershey Medical Center and Cancer InstituteHersheyUSA